University of Strasbourg
Institut de Chimie, UMR UDS CNRS 7177,
Laboratoire de Chimie Biologique et Applications thérapeutiques

Assistant Professor, Faculty of Chemistry, University of Strasbourg

Laboratoire de Chimie Biologique et Applications Thérapeutiques,
Université de Strasbourg, Institut Le Bel,
4 rue Blaise Pascal,
67070 Strasbourg Cedex, France

+33 (0)3 68 85 12 20



Background and expertise of the representative

Philippe Chaignongraduated from the “Ecole Nationale Supérieure de Chimie de Toulouse” in 1999, then obtained his PhD in 2003 under the supervision of Dr. Ouazzani, in the “Institut de Chimie des Substances Naturelles (ICSN)” in Gif sur Yvette. As a post-doctoral fellow, he first worked on biofilm of clinical strains of Staphylococcus at the University of Littoral, then searched for fluorinase in the research group of Dr. Badet at the ICSN. In September 2006, he was appointed Assistant Professor at the University of Strasbourg in the Institute of Chemistry (UMR 7177), a CNRS-University of Strasbourg Institute, with a long-established recognition in the field of terpenoids. He is an active member of the “Chimie Biologique et Applications Thérapeutiques” (CBAT) team directed by Dr. Myriam Seemann.

His research topics at the interface between chemistry and biology aim at the discovery of new inhibitors targeting the methylerythritol phosphate (MEP) pathway, a target for the development of new antibacterial and antiparasitic drugs. He is currently involved in the organic synthesis of mechanism-based inhibitors of LytB, the last enzyme of the MEP pathway, but he is also designing new inhibitors of other enzymes of this pathway using fragment-based drug discovery (FBDD). Philippe Chaignon is the coordinator of the MENAX project who received funding from the ANR in the frame of a Young researcher call (2016). His research achievements in the field of antimicrobial drug development was published in well-ranked journals (e.g. Angewandte Chemie, JACS, FEMS Immunol. Med. Microbiol.).

Organisation profile

The University of Strasbourg (UNISTRA) is one of the largest universities in France, with nearly 50 100 students (including 19, 7% of international students) and over 2 645 teachers-researchers. The University also offers access to 25 modern languages, multinational diplomas, jointly supervised doctorates, upholding renowned international postgraduate schools and student exchange agreements. The scale of research activity at Strasbourg is substantial, involving a European Doctoral College, 10 doctoral schools and 73 research units.

Research is a major asset for the University’s international development. Thanks to the worldwide reputation of its research teams, built on excellence and efficiency, the University of Strasbourg emerges among Europe’s foremost research universities and is a founding member of the League of the European Research Universities (LERU).

The scientific excellence in Chemical and Biological sciences was built through the ages by famous scientists like Louis Pasteur but also many Nobel Laureates such as Emil Fischer, Jean-Marie Lehn, Jules Hofmann (2011), Martin Karplus (2013) and Jean-Pierre Sauvage (2016).

The Strasbourg Institute of Chemistry (ICS, UMR 7177) is an interdisciplinary mixed research unit of the Centre National de la Recherche Scientifique (CNRS) and the University of Strasbourg (UNISTRA) and comprises 300 members. Its research is dedicated to enhancing knowledge in chemistry and addressing major issues such as environment preservation, new energy sources but also development of new therapies.  

The Biological Chemistry and Therapeutic Applications (CBAT) team at ICS is devoted to the study of proteins with therapeutic potential. Its current research focuses on inhibition of enzymes that are targets for the design of new antibacterials with a major interest in the MEP pathway. One of its last achievements is the conception of the two best LytB inhibitors known to date.

Contribution to the network

The CBAT team will participate in the network by bringing its expertise in bioorganic and bioinorganic chemistry. Indeed, the last two enzymes (GcpE and LytB) of the MEP pathway are metalloenzymes harbouring an oxygen sensitive [4Fe-4S] center. The CBAT team masters all the innovative knowledge and technologies needed to handle and characterize oxygen sensitive enzymes as well as the synthesis of substrate analogues of the MEP pathway. Therefore, this team can bring innovative bioactive molecules to the network but also test some compounds on oxygen sensitive enzymes.